JP2018516913A5 - - Google Patents

Info

Publication number

JP2018516913A5

JP2018516913A5 JP2017561747A JP2017561747A JP2018516913A5 JP 2018516913 A5 JP2018516913 A5 JP 2018516913A5 JP 2017561747 A JP2017561747 A JP 2017561747A JP 2017561747 A JP2017561747 A JP 2017561747A JP 2018516913 A5 JP2018516913 A5 JP 2018516913A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

cells

agent

therapeutically effective

antigen receptor

Prior art date

2016-05-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims description 87
• 239000003795 chemical substances by application Substances 0.000 claims description 53
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 51
• 239000013598 vector Substances 0.000 claims description 26
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
• 239000000427 antigen Substances 0.000 claims description 18
• 102000036639 antigens Human genes 0.000 claims description 18
• 108091007433 antigens Proteins 0.000 claims description 18
• 230000008685 targeting Effects 0.000 claims description 17
• 230000006786 activation induced cell death Effects 0.000 claims description 16
• 230000006870 function Effects 0.000 claims description 14
• 206010028980 Neoplasm Diseases 0.000 claims description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
• 230000011664 signaling Effects 0.000 claims description 12
• 231100000433 cytotoxic Toxicity 0.000 claims description 9
• 230000001472 cytotoxic effect Effects 0.000 claims description 9
• 201000011510 cancer Diseases 0.000 claims description 6
• 201000010099 disease Diseases 0.000 claims description 6
• 208000035475 disorder Diseases 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• 239000013612 plasmid Substances 0.000 claims description 4
• 239000013603 viral vector Substances 0.000 claims description 4
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
• 229930186217 Glycolipid Natural products 0.000 claims description 3
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
• 102000003735 Mesothelin Human genes 0.000 claims description 3
• 108090000015 Mesothelin Proteins 0.000 claims description 3
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
• 125000000539 amino acid group Chemical group 0.000 claims description 3
• 230000000139 costimulatory effect Effects 0.000 claims description 3
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
• 238000012737 microarray-based gene expression Methods 0.000 claims description 3
• 239000000203 mixture Substances 0.000 claims description 3
• 239000000178 monomer Substances 0.000 claims description 3
• 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
• 210000002966 serum Anatomy 0.000 claims description 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 34
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
• 238000000034 method Methods 0.000 description 106
• 230000034994 death Effects 0.000 description 6
• 238000002617 apheresis Methods 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000021633 leukocyte mediated immunity Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 239000004055 small Interfering RNA Substances 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 239000000126 substance Substances 0.000 description 1